Alembic Pharma gets EIR from USFDA for API facility at Karakhadi
"The company has received Establishment Inspection Report (EIR) from the US Food and Drug Administration (USFDA) for the inspection carried out by them at our API facility at Karakhadi," the drug firm said in a filing to the BSE.
Alembic Pharmaceuticals Ltd - 533573 - Alembic Pharmaceuticals Limited Receives Establishment Inspection Report (EIR) For Its API Facility At Karakhadi
This is to inform the exchange that the Company has received Establishment Inspection Report (EIR) from US Food and Drug Administration (USFDA) for the inspection carried out by them at our API Facility at Karakhadi during the period from 13th January, 2020 to 17th January, 2020. We request you to kindly take the same on record.
Alembic Pharma share price sheds 4% as USFDA issues 4 observations
The company will provide comprehensive corrective action report to address each observation. ALEMBIC PHARMACEUTICALS LTD. - 533573 - USFDA Inspection At Alembic Pharmaceuticals General Oral Solid Formulation Facility At Panelav
We would like to inform that the US Food and Drug Administration (USFDA) has conducted an inspection at Alembic Pharmaceuticals General Oral Solid Formulation Facility located at Panelav from 9th March, 2020 to 13th March, 2020. This was a scheduled inspection and at the end of the inspection, the USFDA issued a Form 483 with four procedural observations. None of the observations are related to data integrity or repetitive in nature. The Company will provide comprehensive corrective action report to address each observation. The Company is committed to maintaining highest quality standards that meet USFDA standards. We request you to kindly take the same on record. Alembic Pharmaceuticals Ltd - 533573 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Pursuant to Regulation 39(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, this is to inform the exchange that the share certificate(s) of the Company has been reported as lost/misplaced and the registered shareholder(s) have requested the Company for issue of duplicate share certificate(s). We enclose herewith a letter received from Link Intime India Private Limited, Registrar and Share Transfer Agent giving the proof of the date of receipt of aforesaid information by the Company. We request you to kindly take the same on record. Alembic Pharmaceuticals Ltd - 533573 - Corporate Action-Board approves Dividend
With reference to the captioned matter, the exchange is hereby informed that the Board of Directors of Alembic Pharmaceuticals Limited at its meeting held today has declared Interim Dividend of Rs. 7.00/- (350%) per equity share of Rs. 2/- each for the financial year 2019-20 vis-a-vis Rs. 5.50/- (275%) per equity share for the previous year. Further, the Board of Directors declared additional Special Dividend of Rs. 3.00/- (150%) per equity share for the financial year 2019-20. The total Interim Dividend of Rs. 10.00/- (500%) per equity share will be paid to those shareholders whose names appear on the Register of Members as on the Record Date fixed for the purpose i.e. Tuesday, 17th March, 2020. The time of commencement of the Board Meeting was 11:30 a.m. and the time of conclusion was 12:20 p.m. We request you to kindly take the same on record. Alembic Pharmaceuticals Ltd - 533573 - Declaration Of Interim Dividend
With reference to the captioned matter, the exchange is hereby informed that the Board of Directors of Alembic Pharmaceuticals Limited at its meeting held today has declared Interim Dividend of Rs. 7.00/- (350%) per equity share of Rs. 2/- each for the financial year 2019-20 vis-a-vis Rs. 5.50/- (275%) per equity share for the previous year. Further, the Board of Directors declared additional Special Dividend of Rs. 3.00/- (150%) per equity share for the financial year 2019-20. The total Interim Dividend of Rs. 10.00/- (500%) per equity share will be paid to those shareholders whose names appear on the Register of Members as on the Record Date fixed for the purpose i.e. Tuesday, 17th March, 2020. The time of commencement of the Board Meeting was 11:30 a.m. and the time of conclusion was 12:20 p.m. We request you to kindly take the same on record. ALEMBIC PHARMACEUTICALS LTD. - 533573 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
With reference to the captioned subject, this is to inform the exchange that the Company has received US Food & Drug Administration (USFDA) Final Approval for Doxycycline Hyclate Tablets USP, 20 mg. Please find enclosed herewith our press release. We request you to kindly take the same on record. Alembic Pharmaceuticals Ltd - 533573 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclose herewith a copy of Notice of record date fixed for the purpose of Interim Dividend for the financial year 2019-20, published in English and vernacular language (Gujarati) newspaper on 3rd March, 2020 in Economic Times English and Gujarati Edition. We request you to kindly take the same on record. ALEMBIC PHARMACEUTICALS LTD. - 533573 - Corporate Action - Fixes Record Date For Interim Dividend
Pursuant to Regulation 42 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, this is to inform the exchange that the Company has fixed Tuesday, 17th March, 2020 as the Record Date to determine list of shareholders entitled to receive the interim dividend, for the financial year 2019-20, if declared by the Board of Directors at their ensuing meeting scheduled to be held on 6th March, 2020. We request you to kindly take the same on your record and display the same on the website of the Stock Exchange.